HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Warfield, K. L. Articles by Bavari, S. Search for Related Content PubMed PubMed Citation Articles by Warfield, K. L. Articles by Bavari, S. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH

Induction of Humoral and CD8⁺ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection¹

U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702

Ebola virus (EBOV)-like particles (eVLP), composed of the EBOV glycoprotein and matrix viral protein (VP)40 with a lipid membrane, are a highly efficacious method of immunization against EBOV infection. The exact requirements for immunity against EBOV infection are poorly defined at this time. The goal of this work was to determine the requirements for EBOV immunity following eVLP vaccination. Vaccination of BALB/c or C57BL/6 mice with eVLPs in conjunction with QS-21 adjuvant resulted in mixed IgG subclass responses, a Th1-like memory cytokine response, and protection from lethal EBOV challenge. Further, this vaccination schedule led to the generation of both CD4⁺ and CD8⁺ IFN-⁺ T cells recognizing specific peptides within glycoprotein and VP40. The transfer of both serum and splenocytes, but not serum or splenocytes alone, from eVLP-vaccinated mice conferred protection against lethal EBOV infection in these studies. B cells were required for eVLP-mediated immunity to EBOV because B cell-deficient mice vaccinated with eVLPs were not protected from lethal EBOV challenge. We also found that CD8⁺, but not CD4⁺, T cells are absolutely required for eVLP-mediated protection against EBOV infection. Further, eVLP-induced protective mechanisms were perforin-independent, but IFN--dependent. Taken together, both EBOV-specific humoral and cytotoxic CD8⁺ T cell responses are critical to mediate protection against filoviruses following eVLP vaccination.

This article has been cited by other articles:

				P. Halfmann, H. Ebihara, A. Marzi, Y. Hatta, S. Watanabe, M. Suresh, G. Neumann, H. Feldmann, and Y. Kawaoka Replication-Deficient Ebolavirus as a Vaccine Candidate J. Virol., April 15, 2009; 83(8): 3810 - 3815. [Abstract] [Full Text] [PDF]

				H. Tian, A. Groner, M. Boes, and L.-a. Pirofski Pneumococcal Capsular Polysaccharide Vaccine-Mediated Protection against Serotype 3 Streptococcus pneumoniae in Immunodeficient Mice Infect. Immun., April 1, 2007; 75(4): 1643 - 1650. [Abstract] [Full Text] [PDF]

				W. Dowling, E. Thompson, C. Badger, J. L. Mellquist, A. R. Garrison, J. M. Smith, J. Paragas, R. J. Hogan, and C. Schmaljohn Influences of Glycosylation on Antigenicity, Immunogenicity, and Protective Efficacy of Ebola Virus GP DNA Vaccines J. Virol., February 15, 2007; 81(4): 1821 - 1837. [Abstract] [Full Text] [PDF]